Blueshift Asset Management LLC Acquires Shares of 2,096 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Blueshift Asset Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,096 shares of the biotechnology company’s stock, valued at approximately $262,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter worth approximately $607,000. Teachers Retirement System of The State of Kentucky bought a new stake in Sarepta Therapeutics during the second quarter worth $4,771,000. Simplify Asset Management Inc. raised its position in Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares during the last quarter. Securian Asset Management Inc. bought a new position in Sarepta Therapeutics during the 2nd quarter valued at $1,187,000. Finally, Natixis Advisors LLC purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $1,918,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

SRPT has been the subject of several analyst reports. Guggenheim increased their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Finally, Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $137.94 on Friday. The firm has a market capitalization of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock’s 50-day simple moving average is $122.16 and its two-hundred day simple moving average is $131.43. Sarepta Therapeutics, Inc. has a twelve month low of $78.67 and a twelve month high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.